Work

Supplementary Table 6 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Year: 2023

Type: supplementary-materials

Abstract: Summary of TEAEs by MedDRA preferred term [at least two patients (Part 1a Group A) or ≥10% of patients (Part 1a Group B, Part 1b, Part 2) in the safety population]

DOI: 10.1158/2767-9764.24866729.v1

Authors: Pamela Munster, Nicholas Iannotti, Daniel C. Cho, John M. Kirkwood, Liza C. Villaruz, Geoffrey T. Gibney, F. Stephen Hodi, Niharika B. Mettu, Mark Jones, Jill Bowman, Michael Smith, Mani Lakshminarayanan, Steven O'Day

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4389948668

Cites:

Cited by:

Related to: 10